Target-mediated drug disposition model for drugs that bind to more than one target

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 37, Issue 4, 2010, Pages 323-346

  Gibiansky, Leonid ^a   Gibiansky, Ekaterina ^a  

^a QuantPharm LLC 49 Flints Grove Drive   (United States)

Author keywords

Michaelis Menten approximation; Multi target binding; Nonlinear pharmacokinetics; Quasi steady state approximation; Soluble and membrane bound targets; Target mediated drug disposition

Indexed keywords

ACCURACY; COMPUTER SIMULATION; CONTROLLED STUDY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG RESEARCH; DRUG TARGETING; POPULATION MODEL; PRIORITY JOURNAL; REVIEW; SENSITIVITY ANALYSIS;

ANTIBODIES, MONOCLONAL; BIOLOGICAL AVAILABILITY; CELL MEMBRANE; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; PHARMACOKINETICS; PROTEIN BINDING; TISSUE DISTRIBUTION;

EID: 77956618828     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-010-9163-3     Document Type: Review

References (32)

1. G Levy 1994 Pharmacologic target-mediated drug disposition Clin Pharmacol Ther 56 248 252 10.1038/clpt.1994.134 1:STN:280:DyaK2M%2FgvVGqsw%3D%3D 7924119
2. DE Mager WJ Jusko 2001 General pharmacokinetic model for drugs exhibiting target-mediated drug disposition J Pharmacokinet Pharmacodyn 28 507 532 10.1023/A:1014414520282 1:CAS:528:DC%2BD38XjsFSrtro%3D 11999290 (Pubitemid 34289541)
3. DE Mager W Krzyzanski 2005 Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition Pharm Res 22 10 1589 1596 10.1007/s11095-005-6650-0 1:CAS:528:DC%2BD2MXhtVent7vO 16180117 (Pubitemid 41355898)
4. L Gibiansky E Gibiansky T Kakkar P Ma 2008 Approximations of the target-mediated drug disposition model and identifiability of model parameters J Pharmacokinet Pharmacodyn 35 5 573 591 10.1007/s10928-008-9102-8 1:CAS:528:DC%2BD1cXhsFSmtLrK 19005743
5. L Gibiansky E Gibiansky 2009 Target-mediated drug disposition model: approximations, identifiability of model parameters, and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics Expert Opin Drug Metabol Toxicol 5 7 803 812 10.1517/17425250902992901 1:CAS:528: DC%2BD1MXnsFamsb4%3D
6. L Gibiansky E Gibiansky 2009 Target-mediated drug disposition model: relationships with indirect response models and application to population PK-PD analysis J Pharmacokinet Pharmacodyn 36 4 341 351 10.1007/s10928-009-9125-9 19578985
7. A Marathe W Krzyzanski DE Mager 2009 Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model J Pharmacokinet Pharmacodyn 36 3 199 219 10.1007/s10928-009-9118-8 1:CAS:528:DC%2BD1MXnvVOgs74%3D 19434483
8. X Yan DE Mager W Krzyzanski 2010 Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models J Pharmacokinet Pharmacodyn 37 1 25 47 10.1007/s10928-009-9142-8 1:CAS:528:DC%2BC3cXhtFOjsLg%3D 20012173
9. LA Peletier J Gabrielsson 2009 Dynamics of target-mediated drug disposition Eur J Pharm Sci 38 5 445 464 10.1016/j.ejps.2009.09.007 1:CAS:528:DC%2BD1MXhsVKgsL%2FN 19786099
10. HP Grimm 2009 Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations J Pharmacokinet Pharmacodyn 36 5 407 420 10.1007/s10928-009-9129- 5 1:CAS:528:DC%2BD1MXhtlWitbrP 19728050
11. BF Krippendorff K Kuester C Kloft W Huisinga 2009 Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis J Pharmacokinet Pharmacodyn 36 3 239 260 10.1007/s10928-009-9120-1 1:CAS:528:DC%2BD1MXnvVOgsrY%3D 19554432
12. KR Lees AW Kelman JL Reid B Whiting 1989 Pharmacokinetics of and ACE inhibitor, S-9780, in men: evidence of tissue Binding J Pharmacokinet Pharmacodyn 17 5 529 550 1:CAS:528:DyaK3cXhtFWntbs%3D
13. Tannenbaum S, Gautier A, Lowe P (2008) A mechanism based binding model for the population pharmacokinetics and pharmacodynamics of canakinumab, a monoclonal antibody in development for rheumatoid arthritis. AAPS J 10(S2). www.aapsj.org/abstracts/AM-2008/AAPS2008-002581.PDF
14. Retlich S, Duval V, Graefe-Mody U, Jaehde U, Staab A (2010) Impact of target-mediated drug disposition on linagliptin pharmacokinetics and dpp-4 inhibition in type 2 diabetic patients. J Clin Pharmacol. doi: 10.1177/0091270009356444
15. E Snoeck P Jacqmin A Van Peer M Danhof 2009 A combined specific target site binding and pharmacokinetic model to explore the non-linear disposition of draflazine J Pharmacokinet Biopharm 27 3 257 281 10.1023/A:1020943029130
16. J Bostrom SF Yu D Kan BA Appleton CV Lee K Billeci W Man F Peale S Ross C Wiesmann G Fuh 2009 Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site Science 323 5921 1610 1614 10.1126/science.1165480 1:CAS:528:DC%2BD1MXjt1Cqurw%3D 19299620
17. European Medicines Agency (EMEA) (2008) European public assessment report-RoActemra. EMEA website
18. CG Meulen JH Göertz IS Klasen CM Verweij LB Hilbrands JF Wetzels AJ Hoitsma 2003 Decreased renal excretion of soluble interleukin-2 receptor alpha after treatment with daclizumab Kidney Int 64 2 697 703 10.1046/j.1523-1755. 2003.00116.x 12846768 (Pubitemid 36871944)
19. I Nestorov A Munafo O Papasouliotis J Visich 2008 Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis J Clin Pharmacol 48 406 417 10.1177/0091270008315312 1:CAS:528:DC%2BD1cXkslKntL4%3D 18303125 (Pubitemid 351389119)
20. Kuester K, Kloft C (2006) Pharmacokinetics of monoclonal antibodies. In: Meibohm B (ed) Pharmacokinetics and pharmacodynamics of biotech drugs: principles and case studies in drug development. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, pp 45-91
21. DR Mould KD Sweeney 2007 A review of the pharmacokinetics and pharmacodynamics of monoclonal antibodies-mechanistic modeling applied to drug development Current Opin Drug Discov Dev 10 1 84 96 1:CAS:528: DC%2BD2sXpsVGksw%3D%3D
22. W Wand EQ Wang JP Balthasar 2008 Monoclonal antibody pharmacokinetics and pharmacodynamics Clin Pharmacol Ther 84 5 548 558 10.1038/clpt.2008.170
23. HS Moeniralam WA Bemelman E Endert R Koopmans HP Sauerwein JA Romijn 1997 The decrease in nonsplenic interleukin-6 (IL-6) production after splenectomy indicates the existence of a positive feedback loop of IL-6 production during endotoxemia in dogs Infect Immun 65 6 2299 2305 1:CAS:528:DyaK2sXjsFWnsb4%3D 9169767
24. ZY Lu H Brailly J Wijdenes R Bataille JF Rossi B Klein 1995 Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments Blood 86 8 3123 3131 1:CAS:528:DyaK2MXos1ynsbw%3D 7579407
25. T Taguchi 1988 Phase I study of recombinant human tumor necrosis factor (rHu-TNF:PT-050) Cancer Detect Prev 12 1-6 561 572 1:STN:280: DyaL1M%2FivVGjtw%3D%3D 3180146
26. T Moritz N Niederle J Baumann D May E Kurschel R Osieka J Kempeni E Schlick CG Schmidt 1989 Phase I study of recombinant human tumor necrosis factor alpha in advanced malignant disease Cancer Immunol Immunother 29 2 144 145 10.1007/BF00199290 1:STN:280:DyaL1M3kvFSktw%3D%3D 2720707
27. UC Wargalla RA Reisfeld 1989 Rate of internalization of an immunotoxin correlates with cytotoxic activity against human tumor cells Proc Natl Acad Sci USA 86 5146 5150 10.1073/pnas.86.13.5146 1:CAS:528:DyaL1MXkvV2qsrk%3D 2544891
28. Beal SL, Sheiner LB, Boeckmann AJ, Bauer RJ (1989-2009) NONMEM user's guides. Icon Development Solutions, Ellicott City
29. Kakkar T, Gibiansky L, Ma P (2009) Population pharmacokinetics of AMG 317, a fully human anti-IL-4Rα IgG2 monoclonal antibody evaluated in healthy and asthmatic subjects. AAPS J 11(S2). www.aapsj.org/abstracts/AM-2009/ AAPS2009-002216.PDF
30. N Hayashi Y Tsukamoto WM Sallas PJ Lowe 2007 A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab Br J Clin Pharmacol 63 5 548 561 10.1111/j.1365-2125.2006.02803.x 1:CAS:528:DC%2BD2sXntFOrs7w%3D 17096680 (Pubitemid 46632569)
31. Tannenbaum S, Chakraborty A, Rordorf C, Gautier A, Lowe P (2009) Pharmacokinetics of canakinumab and pharmacodynamics of IL-1β binding in patients with cryopyrin associated periodic fever syndromes, Abstr 1592. p 8. www.page-meeting.org/?abstract=1592
32. Vu T, Lee E, Narayanan N, Jang G, Ma P (2010) Predicting free sclerostin from free AMG 785 and total sclerostin, Abstr 1939. p 19. www.page-meeting.org/? abstract=1939